Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04439760
Other study ID # transcranial Doppler
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date July 1, 2022

Study information

Verified date July 2022
Source Kasr El Aini Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess blood flow velocity in middle cerebral artery measured by transcranial doppler to determine the efficacy of SCG block in decreasing incidence or severity of vasospasm after MCA aneurysm surgery.


Description:

Sympathetic innervation to the face and head is by superior cervical ganglion(SCG), which is the most cranial part of the sympathetic chain. It is suited in a plication of the prevertebral fascia anterior to the longuscapitis muscle and dorsal to the internal carotid artery, posteromedial to the vagus nerve at c3 level. It's mainly located at the level of the transverse processes of the second and third cervical vertebrae. However, it may reach caudally to the upper border of the fourth cervical vertebra. Noradrenergic sympathetic nerve fibers mainly originating in the superior cervical ganglion, accompanying the carotid artery supply cerebral vasculature particularly the pial vessels. Superior cervical ganglion block was previously tried in managing neuropathic pain, neuropathic pain in head and face region was investigated in patients using ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion (SCG) ,The short-term analgesic effect of the first blockade by GLOA was significant with a mean pain reduction of 52% (p < 0.001). Superior cervical ganglion block also used as an alternative treatment to tinnitus not responding to conventional therapy, it increases cholear blood flow and this can explain the efficacy of block. Superior cervical ganglion block was used to improve cerebral perfusion in patients with cerebral vasospasm after aSAH. Aneurysmal subarachnoid hemorrhage (aSAH) may develop vasospasm in 70% of patients. Morphological changes occur in the cerebral vessels after SAH, and the inflammatory response and local chemical agents are responsible for the induction of vasospasm. Vasospasm is rare in the first 3 days after SAH, it reaches peak incidence at 7 to10 days and usually resolves by 10 to14 days after SAH. The sympathetic system also has a role in the pathogenesis of this process, cervical sympathetic stimulation leads to constriction in intracerebral vessels and dilation occurs when these fibers are interrupted. Efflux and reuptake of the neurotransmitter may be prevented by sympathectomy. Common treatments to reduce vasospasm include ;triple H therapy (hypertension ,hypervolemia and hemodilution), intraarterial infusion of Smooth muscle relaxants (papaverine, Verapamil) and endovascular balloon angioplasty . Also (nimodipine) calcium channel blocker administration is used as a prophylactic measures. Transcranial doppler (TCD) is a non-invasive technique which can be used to observe velocity, direction and properties of blood flow in the cerebral arteries by means of a pulsed ultrasonic beam, based on the Doppler effect of ultrasounds concerning frequency variations in sound waves as a result of relative motion between source and signal receiver. It was previously used in traumatic brain injury(TBI),stroke, anesthesia and intensive care.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date July 1, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients aged from 18 to 70 years. - Genders eligible for study: both sexes. - ASA I-II. - GCS (13-15) Exclusion Criteria: - Patient refusal - Contraindications to regional anesthesia (Bleeding disorders, Use of any anti-coagulants, local infection). - Known allergy to local anesthetics. - ASA III-IV. - Patients aged less than 18 or more than 70.

Study Design


Intervention

Procedure:
Superior Cervical Ganglion Block
Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.

Locations

Country Name City State
Egypt kasr Al Ainy hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Fatma Ibrahim El Sayed Salman

Country where clinical trial is conducted

Egypt, 

References & Publications (6)

Koning HM, Dyrbye BA, van Hemert FJ. Percutaneous Radiofrequency Lesion of the Superior Cervical Sympathetic Ganglion in Patients with Tinnitus. Pain Pract. 2016 Nov;16(8):994-1000. doi: 10.1111/papr.12348. Epub 2015 Aug 27. — View Citation

Kurth CD, Wagerle LC, Delivoria-Papadopoulos M. Sympathetic regulation of cerebral blood flow during seizures in newborn lambs. Am J Physiol. 1988 Sep;255(3 Pt 2):H563-8. — View Citation

Rumalla K, Smith KA, Arnold PM, Mittal MK. Subarachnoid Hemorrhage and Readmissions: National Rates, Causes, Risk Factors, and Outcomes in 16,001 Hospitalized Patients. World Neurosurg. 2018 Feb;110:e100-e111. doi: 10.1016/j.wneu.2017.10.089. Epub 2017 Oct 26. — View Citation

Sharma AK, Bathala L, Batra A, Mehndiratta MM, Sharma VK. Transcranial Doppler: Techniques and advanced applications: Part 2. Ann Indian Acad Neurol. 2016 Jan-Mar;19(1):102-7. doi: 10.4103/0972-2327.173407. — View Citation

Siegenthaler A, Haug M, Eichenberger U, Suter MR, Moriggl B. Block of the superior cervical ganglion, description of a novel ultrasound-guided technique in human cadavers. Pain Med. 2013 May;14(5):646-9. doi: 10.1111/pme.12061. Epub 2013 Feb 25. — View Citation

Tuor UI. Local distribution of the effects of sympathetic stimulation on cerebral blood flow in the rat. Brain Res. 1990 Oct 8;529(1-2):224-31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Blood flow velocity in middle cerebral artery measured by transcranial doppler (TCD) Change in Blood flow velocity in patients with ruptured aneurysmal subarachnoid hemorrhage undergoing MCA aneurysmal surgeries measured by transcranial doppler The day before surgery (TCD0), Postoperative at day 3 and day 7 (TCD3 & TCD7)
Secondary Incidence or severity of MCA postoperative spasm over 14 days. TCD MCA vasospasm diagnostic criteria :
Proximal MCA vasospasm can be diagnosed by any of the following:
MCA Mean flow velocities of > 200 cm/s, Rapid rise in flow velocities (> 65 cm/s in one day), or Lindegaard ratio (VMCA/VICA >6).
within 14 days
Secondary Change from baseline heart rate Heart rate will be measured Baseline (Before surgery) ,after induction the block and at the end of surgery
Secondary Change from baseline mean arterial blood pressure Mean arterial blood pressure will be measured Baseline (Before surgery) ,after induction the block and at the end of surgery
Secondary Change from baseline oxygen saturation (Sao2) Oxygen saturation (Sao2) will be measured Baseline (Before surgery) ,after induction the block and at the end of surgery
Secondary Incidence of complications (Nerve injury, Hematoma formation, LA toxicity, Sensory or motor deficit, respiratory depression). Incidence of complications (Nerve injury, Hematoma formation, LA toxicity, Sensory or motor deficit, respiratory depression) will be assisted within 14 days
Secondary Glasgow coma scale Glasgow coma scale will be calculated Baseline (Preopetative), at day 3 and day 7
See also
  Status Clinical Trial Phase
Recruiting NCT02345395 - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms N/A
Active, not recruiting NCT05626504 - Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Completed NCT01716117 - Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms N/A
Completed NCT04553549 - Safety and Feasibility of the Infinity Catheter for Radial Access
Completed NCT01975233 - WEB French Observatory of the WEB Aneurysm Embolization System
Terminated NCT01557036 - Aneurysm Study of Pipeline in an Observational Registry N/A
Completed NCT02435823 - Safety Study of the PulseRider® in Patients Undergoing Treatment for Bifurcation Intracranial Aneurysms N/A
Completed NCT03844334 - CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms
Active, not recruiting NCT03852680 - Current Treatment Modalities for Wide Necked Intracranial Aneurysms N/A
Completed NCT01444664 - Aneurysm Wall Histology Registry Phase 4
Recruiting NCT03936647 - The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices N/A
Completed NCT02687607 - CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms
Withdrawn NCT02037932 - Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry Phase 4
Recruiting NCT06456814 - Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China
Recruiting NCT05317169 - Aneurysm Genetic Risk in Patients With QIB Changes
Terminated NCT00537134 - Trial on Endovascular Aneurysm Management N/A